132 related articles for article (PubMed ID: 34998840)
1. cMET: a prognostic marker in papillary renal cell carcinoma?
Erlmeier F; Bruecher B; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Mondorf Y; Ivanyi P; Mikuteit M; Steffens S;
Hum Pathol; 2022 Mar; 121():1-10. PubMed ID: 34998840
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma.
Mikuteit M; Zschäbitz S; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Duensing S; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos F; Walter B; Otto W; Burger M; Erlmeier M; Schrader AJ; Hartmann A; Erlmeier F; Steffens S;
Urol Int; 2023; 107(7):713-722. PubMed ID: 37348477
[TBL] [Abstract][Full Text] [Related]
3. The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma.
Mondorf Y; Mikuteit M; Ivanyi P; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief CG; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Steffens S; Erlmeier F
Urol Int; 2022; 106(11):1168-1176. PubMed ID: 35654002
[TBL] [Abstract][Full Text] [Related]
4. Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study.
Erlmeier F; Steffens S; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Ivanyi P;
Clin Genitourin Cancer; 2021 Feb; 19(1):53-59.e1. PubMed ID: 32778505
[TBL] [Abstract][Full Text] [Related]
5. The prognostic impact of Claudin 6 in papillary renal cell carcinoma.
Mikuteit M; Zschäbitz S; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Steffens S; Erlmeier F
Pathol Res Pract; 2022 Mar; 231():153802. PubMed ID: 35180650
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor.
Schiefer AI; Mesteri I; Berghoff AS; Haitel A; Schmidinger M; Preusser M; Birner P
Histopathology; 2015 Dec; 67(6):799-805. PubMed ID: 25847631
[TBL] [Abstract][Full Text] [Related]
7. Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines.
Yang Y; Ricketts CJ; Vocke CD; Killian JK; Padilla-Nash HM; Lang M; Wei D; Lee YH; Wangsa D; Sourbier C; Meltzer PS; Ried T; Merino MJ; Metwalli AR; Ball MW; Srinivasan R; Linehan WM
Genes Chromosomes Cancer; 2021 Jun; 60(6):434-446. PubMed ID: 33527590
[TBL] [Abstract][Full Text] [Related]
8. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus.
Kim KH; You D; Jeong IG; Kwon TW; Cho YM; Hong JH; Ahn H; Kim CS
BJU Int; 2012 Dec; 110(11 Pt B):E673-8. PubMed ID: 22973869
[TBL] [Abstract][Full Text] [Related]
9. Biphasic papillary (biphasic squamoid alveolar) renal cell carcinoma: a clinicopathologic and molecular study of 17 renal cell carcinomas including 10 papillary adenomas.
Nova-Camacho LM; Acosta AM; Akgul M; Panizo A; Galea LA; Val-Carreres A; Talavera JA; Guerrero-Setas D; Martin-Arruti M; Ruiz I; García-Martos M; Sangoi AR
Virchows Arch; 2024 Mar; 484(3):441-449. PubMed ID: 38388964
[TBL] [Abstract][Full Text] [Related]
10. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population.
Lindor NM; Dechet CB; Greene MH; Jenkins RB; Zincke MT; Weaver AL; Wilson M; Zincke H; Liu W
Genet Test; 2001; 5(2):101-6. PubMed ID: 11551094
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of CMET is associated with signal transducer and activator of transcription 3 activation and diminished prognosis in oesophageal adenocarcinoma but not in squamous cell carcinoma.
Mesteri I; Schoppmann SF; Preusser M; Birner P
Eur J Cancer; 2014 May; 50(7):1354-60. PubMed ID: 24565853
[TBL] [Abstract][Full Text] [Related]
12. Three-dimensional coculture provides an improved in vitro model for papillary renal cell carcinoma.
Rosette KA; Lander SM; VanOpstall C; Looyenga BD
Am J Physiol Renal Physiol; 2021 Jul; 321(1):F33-F46. PubMed ID: 34029144
[TBL] [Abstract][Full Text] [Related]
13. High CENPA expression in papillary renal cell carcinoma tissues is associated with poor prognosis.
Li J; Li Q; Yuan Y; Xie Y; Zhang Y; Zhang R
BMC Urol; 2022 Sep; 22(1):157. PubMed ID: 36163007
[TBL] [Abstract][Full Text] [Related]
14. Expression of nectin-4 in papillary renal cell carcinoma.
Zschäbitz S; Mikuteit M; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Duensing S; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Erlmeier F; Steffens S
Discov Oncol; 2022 Sep; 13(1):90. PubMed ID: 36136143
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in a prospective series of papillary renal cell carcinoma.
Gontero P; Ceratti G; Guglielmetti S; Andorno A; Terrone C; Bonvini D; Faggiano F; Tizzani A; Frea B; Valente G
BJU Int; 2008 Sep; 102(6):697-702. PubMed ID: 18489525
[TBL] [Abstract][Full Text] [Related]
16. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma.
Pahwa R; Dubhashi J; Singh A; Jailwala P; Lobanov A; Thomas CJ; Ceribelli M; Wilson K; Ricketts CJ; Vocke CD; Wells C; Bottaro DP; Linehan WM; Neckers L; Srinivasan R
J Exp Clin Cancer Res; 2022 Jun; 41(1):208. PubMed ID: 35754026
[TBL] [Abstract][Full Text] [Related]
18. Morphological subtyping of papillary renal cell carcinoma: clinicopathological characteristics and prognosis.
Yamashita S; Ioritani N; Oikawa K; Aizawa M; Endoh M; Arai Y
Int J Urol; 2007 Aug; 14(8):679-83. PubMed ID: 17681054
[TBL] [Abstract][Full Text] [Related]
19. Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma.
Margulis V; Tamboli P; Matin SF; Swanson DA; Wood CG
Cancer; 2008 Apr; 112(7):1480-8. PubMed ID: 18240184
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of the magnetic resonance imaging appearance in papillary renal cell carcinoma.
Rosenkrantz AB; Sekhar A; Genega EM; Melamed J; Babb JS; Patel AD; Lo A; Najarian RM; Ahmed M; Pedrosa I
Eur Radiol; 2013 Feb; 23(2):579-87. PubMed ID: 22903703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
